Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease

Juan Pablo Arab, Melisa Dirchwolf, Mário Reis Álvares-da-Silva, Francisco Barrera, Carlos Benítez, Marlene Castellanos-Fernandez, Graciela Castro-Narro, Norberto Chavez-Tapia, Daniela Chiodi, Helma Cotrim, Kenneth Cusi, Claudia Pinto Marques Souza de Oliveira, Javier Díaz, Eduardo Fassio, Solange Gerona, Marcos Girala, Nelia Hernandez, Sebastián Marciano, Walter Masson, Nahum Méndez-SánchezNathalie Leite, Adelina Lozano, Martín Padilla, Arturo Panduro, Raymundo Paraná, Edison Parise, Marlene Perez, Jaime Poniachik, Juan Carlos Restrepo, Andrés Ruf, Marcelo Silva, Martín Tagle, Monica Tapias, Kenia Torres, Eduardo Vilar-Gomez, José Eduardo Costa Gil, Adrian Gadano, Marco Arrese

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chronic liver disease, affecting 20–30% of the general population. Furthermore, its prevalence is predicted to increase exponentially in the next decades, concomitantly with the global epidemic of obesity, type 2 diabetes mellitus (T2DM), and sedentary lifestyle. NAFLD is a clinical syndrome that encompasses a wide spectrum of associated diseases and hepatic complications such as hepatocellular carcinoma (HCC). Moreover, this disease is believed to become the main indication for liver transplantation in the near future. Since NAFLD management represents a growing challenge for primary care physicians, the Asociación Latinoamericana para el Estudio del Hígado (ALEH) has decided to organize this Practice Guidance for the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease, written by Latin-American specialists in different clinical areas, and destined to general practitioners, internal medicine specialists, endocrinologists, diabetologists, gastroenterologists, and hepatologists. The main purpose of this document is to improve patient care and awareness of NAFLD. The information provided in this guidance may also be useful in assisting stakeholders in the decision-making process related to NAFLD. Since new evidence is constantly emerging on different aspects of the disease, updates to this guideline will be required in future.

Original languageEnglish
Pages (from-to)674-690
Number of pages17
JournalAnnals of Hepatology
Volume19
Issue number6
DOIs
StatePublished - 1 Nov 2020

Bibliographical note

Publisher Copyright:
© 2020

Keywords

  • Cirrhosis
  • Clinical practice guidance
  • Fatty liver
  • MAFLD
  • NAFLD
  • NASH
  • Nonalcoholic fatty liver disease
  • Nonalcoholic steatohepatitis
  • Steatosis

Fingerprint

Dive into the research topics of 'Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease'. Together they form a unique fingerprint.

Cite this